Côd QR

Codon-specific KRAS mutations predict survival in advanced pancreatic cancer

Background: How distinct KRAS alterations in pancreatic adenocarcinoma (PDAC) influence tumor initiation and outcomes remains unclear. Moreover, KRAS is now partly targetable with novel specific inhibitors targeting KRASG12 (G12C or G12D), but specific outcomes of these subgroups of patients is poor...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: A. Boilève, A. Rousseau, M. Hilmi, A. Tarabay, J.R.R. Mathieu, J. Cartry, S. Bedja, N. Goudarzi, C. Nicotra, M. Ngo-Camus, V. Boige, M. Valéry, T. Pudlarz, M.-A. Bani, P. Dartigues, L. Tselikas, A. Italiano, S. Cosconea, M. Gelli, E. Fernandez-de-Sevilla, D. Malka, M. Annereau, F. Jaulin, C. Smolenschi, A. Hollebecque, M. Ducreux
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Elsevier 2024-03-01
Cyfres:ESMO Gastrointestinal Oncology
Pynciau:
precision medicine
KRAS
pancreatic cancer
Mynediad Ar-lein:http://www.sciencedirect.com/science/article/pii/S2949819823000456
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg